Fundraising FoxHarmonix Fund — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.
AI & Machine LearningBiotechMedical DevicesNatick, US
Edward Doherty(Executive Officer)Jessica McDonough(Director)Joaquim Trias(Executive Officer, Director)
BoardZeshan Muhammedi(Director)in
Co-investorsAAF Management Ltd.Divergent CapitalEmbark VenturesMBX CapitalUlu VenturesAxial VC
Loft Orbital operates space infrastructure, providing satellites equipped with sensing resources, onboard edge compute, and connectivity that let customers run missions without deploying their own hardware.
AI & Machine LearningDeep TechDefense TechHardwareSpace TechSan Francisco, US
Antoine Bellon de Chassy(Executive Officer, Director)Pierre-Damien Vaujour(Founder)inAlex Greenberg(Founder)inAntoine de Chassy(Founder)
Co-investors1809 CapitalAlumni VenturesBlast.ClubBlitzscaling VenturesChaos VenturesEQUIAM+22 more
Sorcero develops AI-powered intelligence solutions for the life sciences industry, helping companies accelerate patient access to therapies and improve medical research and communications.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechMedical DevicesWashington, US
Dipanwita Das(CEO and Co-founder)inRichard Graves(Executive Officer, Director)inWalter Bender(CTO)inClaiborne P. Deming(Director)
BoardOliver Libby(Director)inPeter Hart Callahan(Director)
Co-investorsAlumni VenturesFirst Trust Capital PartnersJanuary VenturesKoru CapitalMighty CapitalMount Pleasant Ventures+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Scribe Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.